BioSpecifics Technologies is a biopharmaceutical company which engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company offers injectable collagenase in Canada and Australia, as well as in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The Company is also involved in the development of other clinical indications for which collagenase injection has been tested.
Type | Public | |
Founded | 1957 | |
HQ | Lynbrook, NY, US | Map |
Website | biospecifics.com |
USD | |
---|---|
Revenue (Q2, 2020) | 3.9m |
Net income (Q2, 2020) | 115.8k |
EBIT (Q2, 2020) | (250.9k) |
Market capitalization (17-Dec-2020) | 650.2m |
Closing stock price (17-Dec-2020) | 88.5 |
Cash (30-Jun-2020) | 16.9m |
EV | 633.6m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 5.0m | 1.9m | 2.6m | 2.6m | 2.4m | 4.0m | 3.3m | 3.1m | 2.8m | 2.7m | 4.0m | 5.6m | 4.7m | 6.3m | 6.6m | 6.2m | 6.9m | 7.7m | 6.5m | 6.5m | 7.1m | 7.1m | 8.2m | 8.1m | 8.9m | 9.4m | 9.7m | 3.9m |
General and administrative expense | 1.4m | 1.2m | 1.1m | 1.1m | 1.4m | 1.6m | 1.2m | 1.1m | 1.2m | 1.5m | 1.8m | 1.8m | 1.7m | 2.2m | 1.9m | 1.8m | 2.4m | 2.3m | 2.2m | 2.1m | 2.0m | 2.2m | 2.9m | 1.7m | 2.0m | 3.2m | 4.0m | |
R&D expense | 270.8k | 224.2k | 249.6k | 404.3k | 293.2k | 294.9k | 470.0k | 346.8k | 382.7k | 286.3k | 239.5k | 256.7k | 258.8k | 248.5k | 444.5k | 312.9k | 254.8k | 337.7k | 356.8k | 195.2k | 211.8k | 162.6k | 149.5k | 161.3k | 143.2k | 122.0k | 160.5k | |
Operating expense total | 1.7m | 1.5m | 1.3m | 1.6m | 1.7m | 1.9m | 1.7m | 1.4m | 1.6m | 1.8m | 2.0m | 2.1m | 2.0m | 2.4m | 2.3m | 2.2m | 2.7m | 2.7m | 2.5m | 2.3m | 2.2m | 2.4m | 3.1m | 1.9m | 2.1m | 3.3m | 4.2m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 5.0m | 3.8m | 5.8m | 3.8m | 3.8m | 7.2m | 4.0m | 4.6m | 8.9m | 8.8m | 9.7m | 10.7m | 8.5m | 7.5m | 9.5m | 7.0m | 4.7m | 9.0m | 6.0m | 6.4m | 12.6m | 13.0m | 13.4m | 17.6m | 14.0m | 12.8m | 19.1m | 16.9m |
Accounts Receivable | 877.4k | 1.7m | 1.8m | 2.8m | 3.2m | 2.9m | 3.9m | 5.0m | 1.9m | 2.0m | 3.1m | 3.7m | 3.0m | 4.2m | 3.8m | 4.3m | 3.8m | 4.9m | 4.7m | 4.7m | 19.2m | 12.9m | 14.5m | 16.5m | 16.7m | 17.8m | 17.8m | 11.7m |
Prepaid Expenses | 151.4k | 122.1k | 167.3k | 219.5k | 161.2k | 363.9k | 411.1k | 444.4k | 327.9k | 291.4k | 382.7k | 236.7k | 469.0k | 258.1k | 467.1k | 730.8k | 554.4k | 583.6k | 800.5k | 673.1k | 580.9k | 837.0k | 802.0k | 604.4k | 1.0m | 836.7k | 898.6k | 1.3m |
Current Assets | 12.9m | 12.3m | 14.1m | 12.7m | 13.1m | 15.6m | 16.4m | 17.0m | 19.5m | 20.3m | 21.8m | 29.0m | 32.7m | 37.5m | 48.2m | 50.6m | 55.4m | 55.2m | 58.4m | 61.6m | 82.7m | 81.4m | 87.7m | 101.6m | 103.0m | 101.4m | 122.9m | 112.1m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|---|
Net Income | 6.6m | 3.0m | 5.3m | 4.6m | 9.6m | 11.4m | 11.3m | 20.1m | 24.5m |
Depreciation and Amortization | 50.7k | 64.2k | 64.3k | 247.1k | 933.0k | 1.7m | 2.2m | 2.4m | 314.2k |
Accounts Payable | (3.0m) | (242.2k) | 121.4k | (90.6k) | 67.3k | 127.6k | 195.3k | 325.6k | (802.5k) |
Cash From Operating Activities | (687.6k) | 2.4m | 5.1m | 6.1m | 10.6m | 16.4m | 13.2m | 17.7m | 22.3m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 6.3m | 6.5m | 742.4k | 1.4m | 1.9m | 1.4m | 2.4m | 3.6m | 754.0k | 1.3m | 2.7m | 2.3m | 4.1m | 7.0m | 2.8m | 5.4m | 8.5m | 3.3m | 6.0m | 8.7m | 4.0m | 8.3m | 13.9m | 4.4m | 10.8m | 17.1m | 4.5m | 4.6m |
Depreciation and Amortization | 21.2k | 32.3k | 12.9k | 29.0k | 43.5k | 16.1k | 32.2k | 96.2k | 89.8k | 176.6k | 94.0k | 172.6k | 319.6k | 647.1k | 414.7k | 816.1k | 1.2m | 545.1k | 1.1m | 1.6m | 699.7k | 1.4m | 2.0m | 153.3k | 150.6k | 202.9k | 22.2k | 45.9k |
Accounts Payable | (1.9m) | (2.8m) | 1.8m | 97.4k | 15.6k | 253.1k | 147.7k | 86.2k | 91.4k | (66.5k) | (303.2k) | 239.9k | 287.7k | 107.4k | 26.7k | (23.6k) | 380.9k | 422.8k | 423.8k | 46.6k | 308.2k | 118.7k | (356.5k) | 146.1k | (1.1m) | (921.4k) | 630.1k | 1.1m |
Cash From Operating Activities | 2.3m | 758.1k | 4.1m | 2.4m | 2.6m | 3.9m | 3.9m | 3.4m | 3.9m | 3.4m | 4.0m | 2.0m | 4.5m | 6.2m | 7.4m | 9.4m | 14.8m | 3.3m | 6.3m | 9.4m | (876.3k) | 8.1m | 12.3m | 6.0m | 9.8m | 14.5m | 8.2m | 14.8m |
USD | Q2, 2011 |
---|---|
Financial Leverage | 1.2 x |
When was BioSpecifics Technologies founded?
BioSpecifics Technologies was founded in 1957.
Who are BioSpecifics Technologies key executives?
BioSpecifics Technologies's key executives are Joseph Truitt, Mike Sherman and Alex Monteith.
How many employees does BioSpecifics Technologies have?
BioSpecifics Technologies has 7 employees.
What is BioSpecifics Technologies revenue?
Latest BioSpecifics Technologies annual revenue is $38.2 m.
What is BioSpecifics Technologies revenue per employee?
Latest BioSpecifics Technologies revenue per employee is $5.5 m.
Who are BioSpecifics Technologies competitors?
Competitors of BioSpecifics Technologies include Nordic Nanovector, Abliva and ViewPoint Therapeutics.
Where is BioSpecifics Technologies headquarters?
BioSpecifics Technologies headquarters is located at 35 Wilbur St, Lynbrook.
Where are BioSpecifics Technologies offices?
BioSpecifics Technologies has offices in Lynbrook and Wilmington.
How many offices does BioSpecifics Technologies have?
BioSpecifics Technologies has 2 offices.
Receive alerts for 300+ data fields across thousands of companies